|
|
|
| Research Progress of Biomarkers for Prognosis Evaluation of HIV- associated Diffuse Large B-cell Lymphoma Patients |
TANG Xin-yi1,2,ZHANG Ya-kun1,2,CHEN Shuang2,PENG Yu2,JIANG Ting-ting2,LIU Yao2,YANG Zai-lin2,**( ) |
1 School of Medicine Chongqing University, Chongqing 400030, China
2 Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Chongqing University Cancer Hospital, Chongqing 400030, China |
|
|
|
Abstract Human immunodeficiency virus (HIV)-associated diffuse large B-cell lymphoma (DLBCL) is a rare disease with high malignancy, complex treatment, poor prognosis, and high mortality rate. Currently, the international prognostic index (IPI) is widely used to assess the prognosis of DLBCL patients. However, due to the uniqueness of HIV infection, HIV-associated DLBCL patients have different clinical characteristics compared to HIV-negative DLBCL patients, and the IPI cannot accurately distinguish HIV-associated DLBCL patients with high risks and poor prognosis. In response to the challenges faced in the prognosis evaluation of HIV-associated DLBCL patients, this review summarizes the research progress of biomarkers for prognosis evaluation of HIV-associated DLBCL patients, providing reference for improving the accuracy of prognosis evaluation of patients with HIV-associated DLBCL.
|
|
Received: 14 October 2023
Published: 16 January 2024
|
|
|
|
|
| [1] |
Cesarman E. Pathology of lymphoma in HIV. Current Opinion in Oncology, 2013, 25(5): 487-494.
doi: 10.1097/01.cco.0000432525.70099.a4
pmid: 23942293
|
|
|
| [2] |
Wang C Y, Liu J, Liu Y. Progress in the treatment of HIV-associated lymphoma when combined with the antiretroviral therapies. Frontiers in Oncology, 2022, 11: 798008.
doi: 10.3389/fonc.2021.798008
|
|
|
| [3] |
Robbins H A, Shiels M S, Pfeiffer R M, et al. Epidemiologic contributions to recent cancer trends among HIV-infected people in the United States. AIDS, 2014, 28(6): 881-890.
doi: 10.1097/QAD.0000000000000163
pmid: 24300545
|
|
|
| [4] |
Shiels M S, Althoff K N, Pfeiffer R M, et al. HIV infection, immunosuppression, and age at diagnosis of non-AIDS-defining cancers. Clinical Infectious Diseases, 2017, 64(4): 468-475.
doi: 10.1093/cid/ciw764
pmid: 27940936
|
|
|
| [5] |
张仁芳, 沈杨, 卢洪洲, 等. AIDS相关性淋巴瘤诊治专家共识. 中国艾滋病性病, 2017, 23(8):678-682.
|
|
|
| [5] |
Zhang R F, Shen Y, Lu H Z, et al. Expert consensus on diagnosis and treatment of AIDS-related lymphoma. Chinese Journal of AIDS & STD, 2017, 23(8):678-682.
|
|
|
| [6] |
Wu D D, Chen C, Zhang M Z, et al. The clinical features and prognosis of 100 AIDS-related lymphoma cases. Scientific Reports, 2019, 9(1): 5381.
doi: 10.1038/s41598-019-41869-9
pmid: 30926889
|
|
|
| [7] |
Schommers P, Hentrich M, Hoffmann C, et al. Survival of AIDS-related diffuse large B-cell lymphoma, Burkitt lymphoma, and plasmablastic lymphoma in the German HIV Lymphoma Cohort. British Journal of Haematology, 2015, 168(6): 806-810.
doi: 10.1111/bjh.13221
pmid: 25403997
|
|
|
| [8] |
Navarro W H, Kaplan L D. AIDS-related lymphoproliferative disease. Blood, 2006, 107(1): 13-20.
doi: 10.1182/blood-2004-11-4278
pmid: 16099881
|
|
|
| [9] |
Ruppert A S, Dixon J G, Salles G, et al. International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI. Blood, 2020, 135(23): 2041-2048.
doi: 10.1182/blood.2019002729
pmid: 32232482
|
|
|
| [10] |
Giagulli C, Marsico S, Magiera A K, et al. Opposite effects of HIV-1 p 17 variants on PTEN activation and cell growth in B cells. PLoS One, 2011, 6(3): e17831.
|
|
|
| [11] |
Linke-Serinsöz E, Fend F, Quintanilla-Martinez L. Human immunodeficiency virus (HIV) and Epstein-Barr virus (EBV) related lymphomas, pathology view point. Seminars in Diagnostic Pathology, 2017, 34(4): 352-363.
doi: S0740-2570(17)30044-8
pmid: 28506687
|
|
|
| [12] |
Nadine R, Nada A, Moosa MahomedYunus S. Prognostic variables and 4-year survival outcomes in CD20 positive AIDS-related lymphoma in the anti-retroviral treatment era: a Retrospective Review from a Single Centre in KwaZulu-Natal, South Africa. PLoS One, 2022, 17(9): e0272282.
|
|
|
| [13] |
Vargas J C, Marques M O, Pereira J, et al. Factors associated with survival in patients with lymphoma and HIV: the largest cohort study in Brazil. AIDS, 2023, 37(8):1217-1226.
doi: 10.1097/QAD.0000000000003549
|
|
|
| [14] |
Barta S K, Samuel M S, Xue X, et al. Changes in the influence of lymphoma- and HIV-specific factors on outcomes in AIDS-related non-Hodgkin lymphoma. Annals of Oncology, 2015, 26(5): 958-966.
doi: S0923-7534(19)31499-1
pmid: 25632071
|
|
|
| [15] |
Yin H L, Qu J N, Peng Q, et al. Molecular mechanisms of EBV-driven cell cycle progression and oncogenesis. Medical Microbiology and Immunology, 2019, 208(5): 573-583.
doi: 10.1007/s00430-018-0570-1
pmid: 30386928
|
|
|
| [16] |
Carbone A, Gloghini A, Caruso A, et al. The impact of EBV and HIV infection on the microenvironmental niche underlying Hodgkin lymphoma pathogenesis. International Journal of Cancer, 2017, 140(6): 1233-1245.
doi: 10.1002/ijc.30473
pmid: 27750386
|
|
|
| [17] |
Vockerodt M, Yap L F, Shannon-Lowe C, et al. The Epstein-Barr virus and the pathogenesis of lymphoma. The Journal of Pathology, 2015, 235(2): 312-322.
doi: 10.1002/path.4459
pmid: 25294567
|
|
|
| [18] |
Shponka V, Reveles C Y, Alam S, et al. Frequent expression of activation-induced cytidine deaminase in diffuse large B-cell lymphoma tissues from persons living with HIV. AIDS, 2020, 34(14): 2025-2035.
doi: 10.1097/QAD.0000000000002653
|
|
|
| [19] |
Chapman J R, Bouska A C, Zhang W W, et al. EBV-positive HIV-associated diffuse large B cell lymphomas are characterized by JAK/STAT (STAT3) pathway mutations and unique clinicopathologic features. British Journal of Haematology, 2021, 194(5): 870-878.
doi: 10.1111/bjh.17708
pmid: 34272731
|
|
|
| [20] |
Muncunill J, Baptista M J, Hernandez-Rodríguez Á, et al. Plasma Epstein-Barr virus load as an early biomarker and prognostic factor of human immunodeficiency virus-related lymphomas. Clinical Infectious Diseases, 2019, 68(5): 834-843.
doi: 10.1093/cid/ciy542
pmid: 29982484
|
|
|
| [21] |
Montgomery N D, Randall C, Painschab M, et al. High pretreatment plasma Epstein-Barr virus (EBV) DNA level is a poor prognostic marker in HIV-associated, EBV-negative diffuse large B-cell lymphoma in Malawi. Cancer Medicine, 2020, 9(2): 552-561.
doi: 10.1002/cam4.2710
pmid: 31782984
|
|
|
| [22] |
Robbins H A, Pfeiffer R M, Shiels M S, et al. Excess cancers among HIV-infected people in the United States. Journal of the National Cancer Institute, 2015, 107(4): dju503.
|
|
|
| [23] |
Coté T R, Biggar R J, Rosenberg P S, et al. Non-Hodgkin’s lymphoma among people with AIDS: incidence, presentation and public health burden. International Journal of Cancer, 1997, 73(5): 645-650.
doi: 10.1002/(sici)1097-0215(19971127)73:5<645::aid-ijc6>3.0.co;2-x
pmid: 9398040
|
|
|
| [24] |
Ramaswami R, Chia G, Dalla Pria A, et al. Evolution of HIV-associated lymphoma over 3 decades. JAIDS Journal of Acquired Immune Deficiency Syndromes, 2016, 72(2): 177-183.
doi: 10.1097/QAI.0000000000000946
|
|
|
| [25] |
Tedeschi R, Bortolin M T, Bidoli E, et al. Assessment of immunovirological features in HIV related non-Hodgkin lymphoma patients and their impact on outcome. Journal of Clinical Virology, 2012, 53(4): 297-301.
doi: 10.1016/j.jcv.2011.12.021
pmid: 22244256
|
|
|
| [26] |
Barta S K, Xue X N, Wang D, et al. Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1546 patients. Blood, 2013, 122(19): 3251-3262.
doi: 10.1182/blood-2013-04-498964
pmid: 24014242
|
|
|
| [27] |
Barta S K, Xue X N, Wang D, et al. A new prognostic score for AIDS-related lymphomas in the rituximab-era. Haematologica, 2014, 99(11): 1731-1737.
doi: 10.3324/haematol.2014.111112
pmid: 25150257
|
|
|
| [28] |
Gandhi R T, Mcmahon D K, Bosch R J, et al. Levels of HIV-1 persistence on antiretroviral therapy are not associated with markers of inflammation or activation. PLoS Pathogens, 2017, 13(4): e1006285.
doi: 10.1371/journal.ppat.1006285
|
|
|
| [29] |
Chen J J, Liu X W, Qin S F, et al. A novel prognostic score including the CD4/CD 8 for AIDS-related lymphoma. Frontiers in Cellular and Infection Microbiology, 2022, 12: 919446.
doi: 10.3389/fcimb.2022.919446
|
|
|
| [30] |
Xu Z P, Zhang J, Zhong Y X, et al. Predictive value of the monocyte-to-lymphocyte ratio in the diagnosis of prostate cancer. Medicine, 2021, 100(38): e27244.
doi: 10.1097/MD.0000000000027244
|
|
|
| [31] |
Bi Q, Wu J Y, Qiu X M, et al. Tumor-associated inflammation: the tumor-promoting immunity in the early stages of tumorigenesis. Journal of Immunology Research, 2022, 2022: 3128933.
|
|
|
| [32] |
Deng Q W, He B S, Liu X, et al. Prognostic value of pre-operative inflammatory response biomarkers in gastric cancer patients and the construction of a predictive model. Journal of Translational Medicine, 2015, 13(1): 66.
doi: 10.1186/s12967-015-0409-0
|
|
|
| [33] |
Mohsen A, Taalab M M, Abousamra N K, et al. Prognostic significance of absolute lymphocyte to absolute monocyte count ratio in Egyptian patients with diffuse large B-cell lymphoma. Clinical Lymphoma Myeloma and Leukemia, 2019, 19: S245.
|
|
|
| [34] |
Zeng J, Zhang X Q, Jia L, et al. Pretreatment lymphocyte-to-monocyte ratios predict AIDS-related diffuse large B-cell lymphoma overall survival. Journal of Medical Virology, 2021, 93(6): 3907-3914.
doi: 10.1002/jmv.26655
pmid: 33155687
|
|
|
| [35] |
Jenifer V, Tracey W, Denise L, et al. The prognostic impact of monocyte fluorescence, immunosuppressive monocytes and peripheral blood immune cell numbers in HIV-associated Diffuse Large B-cell Lymphoma. PLoS One, 2023, 18(1): e0280044.
doi: 10.1371/journal.pone.0280044
|
|
|
| [36] |
Jurisic V, Radenkovic S, Konjevic G. The actual role of LDH as tumor marker, biochemical and clinical aspects. Advances in Experimental Medicine and Biology, 2015, 867: 115-124.
doi: 10.1007/978-94-017-7215-0_8
pmid: 26530363
|
|
|
| [37] |
Park J H, Yoon D H, Kim D Y, et al. The highest prognostic impact of LDH among International Prognostic Indices (IPIs): an explorative study of five IPI factors among patients with DLBCL in the era of rituximab. Annals of Hematology, 2014, 93(10): 1755-1764.
doi: 10.1007/s00277-014-2115-z
pmid: 25027115
|
|
|
| [38] |
Chiara R, Alessandro R, Laura B, et al. Cell-of-origin identification and prognostic correlation in HIV-associated diffuse large B-cell lymphomas: results of an Italian multicentric study. Blood, 2018, 132(Supplement 1): 5294.
doi: 10.1182/blood-2018-99-116437
|
|
|
| [39] |
张玮, 杨翠先, 闵海燕, 等. 乳酸脱氢酶及部分指标在艾滋病相关弥漫大B细胞淋巴瘤病人中的临床意义. 中国艾滋病性病, 2020, 26(9): 936-940.
|
|
|
| [39] |
Zhang W, Yang C X, Min H Y, et al. Clinical significance of lactate dehydrogenase and some indexes in patients with AIDS-related diffuse large B-cell lymphoma. Chinese Journal of AIDS & STD, 2020, 26(9): 936-940.
|
|
|
| [40] |
Painschab M S, Kasonkanji E, Zuze T, et al. Mature outcomes and prognostic indices in diffuse large B-cell lymphoma in Malawi: a prospective cohort. British Journal of Haematology, 2019, 184(3): 364-372.
doi: 10.1111/bjh.15625
pmid: 30450671
|
|
|
| [41] |
Grey H M, Kubo R T, Colon S M, et al. The small subunit of HL-a antigens is beta 2-microglobulin. The Journal of Experimental Medicine, 1973, 138(6): 1608-1612.
doi: 10.1084/jem.138.6.1608
|
|
|
| [42] |
Peterson P A, Cunningham B A, Berggård I, et al. 2-microglobulin-a free immunoglobulin domain. Proceedings of the National Academy of Sciences of the United States of America, 1972, 69(7): 1697-1701.
|
|
|
| [43] |
Wang C Q, Wang Z Q, Yao T T, et al. The immune-related role of beta-2-microglobulin in melanoma. Frontiers in Oncology, 2022, 12: 944722.
doi: 10.3389/fonc.2022.944722
|
|
|
| [44] |
Shi C M, Zhu Y, Su Y P, et al. Beta2-microglobulin: emerging as a promising cancer therapeutic target. Drug Discovery Today, 2009, 14(1-2): 25-30.
doi: 10.1016/j.drudis.2008.11.001
pmid: 19056512
|
|
|
| [45] |
韩颖, 秦燕, 何小慧, 等. 370例晚期弥漫大B细胞淋巴瘤的临床特征和预后分析. 中华肿瘤杂志, 2018, 40(6): 456-461.
doi: 10.3760/cma.j.issn.0253-3766.2018.06.011
pmid: 29936773
|
|
|
| [45] |
Han Y, Qin Y, He X H, et al. Retrospective analysis of the clinical features and prognostic factors of 370 patients with advanced-stage diffuse large B-cell lymphoma. Chinese Journal of Oncology, 2018, 40(6): 456-461.
doi: 10.3760/cma.j.issn.0253-3766.2018.06.011
pmid: 29936773
|
|
|
| [46] |
蒋奕, 胡腾, 江成巧. 艾滋病血清白蛋白、β2微球蛋白和白介素-8水平与肾功能的关系. 河北医药, 2018, 40(20): 3068-3072.
|
|
|
| [46] |
Jang Y, Hu T, Jiang C Q. Correlation between the serum levels of albumin, β2-microglobulin, interleukin 8 and renal function of patients with AIDS. Hebei Medical Journal, 2018, 40(20): 3068-3072.
|
|
|
| [47] |
Szymańska B, Marchewka Z, Knysz B, et al. A panel of urinary biochemical markers for the noninvasive detection of kidney dysfunction in HIV-infected patients. Polish Archives of Internal Medicine, 2019, 129(7-8): 490-498.
|
|
|
| [48] |
王超雨, 刘俊, 梁喜平, 等. 63例HIV相关弥漫大B细胞淋巴瘤临床特征及预后分析:国内单中心真实世界研究. 中华血液学杂志, 2022, 43(3): 203-208.
doi: 10.3760/cma.j.issn.0253-2727.2022.03.004
pmid: 35405777
|
|
|
| [48] |
Wang C Y, Liu J, Liang X P, et al. Clinical characteristics and prognostic features of 63 HIV-associated diffuse large B-cell lymphoma: a single-center real-world study in China. Chinese Journal of Hematology, 2022, 43(3): 203-208.
doi: 10.3760/cma.j.issn.0253-2727.2022.03.004
pmid: 35405777
|
|
|
| [49] |
Dang C V, O’Donnell K A, Zeller K I, et al. The c-Myc target gene network. Seminars in Cancer Biology, 2006, 16(4): 253-264.
doi: 10.1016/j.semcancer.2006.07.014
pmid: 16904903
|
|
|
| [50] |
Chao C, Silverberg M J, Xu L F, et al. A comparative study of molecular characteristics of diffuse large B-cell lymphoma from patients with and without human immunodeficiency virus infection. Clinical Cancer Research, 2015, 21(6): 1429-1437.
doi: 10.1158/1078-0432.CCR-14-2083
pmid: 25589617
|
|
|
| [51] |
Pather S, Patel M. HIV-associated DLBCL: Clinicopathological factors including dual-colour chromogenic in situ hybridisation to assess MYC gene copies. Annals of Diagnostic Pathology, 2022, 58: 151913.
doi: 10.1016/j.anndiagpath.2022.151913
|
|
|
| [52] |
孙晓梅, 梅雯, 何冰, 等. Ki-67、Bcl-6、Bcl-2及TEFM在弥漫大B细胞淋巴瘤中的表达及预后意义. 大理大学学报, 2023, 8(2):62-69.
|
|
|
| [52] |
Sun X M, Mei W, He B, et al. Expression and prognostic significance of Ki-67, Bcl-6, Bcl-2 and TEFM in diffuse large B cell lymphoma. Journal of Dali University, 2023, 8(2):62-69.
|
|
|
| [53] |
Pophali P A, Marinelli L M, Ketterling R P, et al. High level MYC amplification in B-cell lymphomas: is it a marker of aggressive disease? Blood Cancer Journal, 2020, 10(1): 5.
doi: 10.1038/s41408-019-0271-z
pmid: 31932576
|
|
|
| [54] |
Rosenthal A, Younes A. High grade B-cell lymphoma with rearrangements of MYC and BCL2 and/or BCL6: double hit and triple hit lymphomas and double expressing lymphoma. Blood Reviews, 2017, 31(2): 37-42.
doi: S0268-960X(16)30048-0
pmid: 27717585
|
|
|
| [55] |
Swerdlow S. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed. Lyon: IARC, 2017.
|
|
|
| [56] |
McPhail E D, Maurer M J, Macon W R, et al. Inferior survival in high-grade B-cell lymphoma with MYC and BCL2 and/or BCL 6 rearrangements is not associated with MYC/IG gene rearrangements. Haematologica, 2018, 103(11): 1899-1907.
doi: 10.3324/haematol.2018.190157
pmid: 29903764
|
|
|
| [57] |
Scott D W, King R L, Staiger A M, et al. High-grade B-cell lymphoma with MYC and BCL2 and/or BCL 6 rearrangements with diffuse large B-cell lymphoma morphology. Blood, 2018, 131(18): 2060-2064.
doi: 10.1182/blood-2017-12-820605
|
|
|
| [58] |
Hashmi A A, Iftikhar S N, Nargus G, et al. Ki67 proliferation index in germinal and non-germinal subtypes of diffuse large B-cell lymphoma. Cureus, 2021, 13(2): e13120.
|
|
|
| [59] |
Zaiem F, Jerbi R, Albanyan O, et al. High Ki67 proliferation index but not cell-of-origin subtypes is associated with shorter overall survival in diffuse large B-cell lymphoma. Avicenna Journal of Medicine, 2020, 10(4): 241-248.
doi: 10.4103/ajm.ajm_81_20
pmid: 33437697
|
|
|
| [60] |
Maguire A, Chen X F, Wisner L, et al. Enhanced DNA repair and genomic stability identify a novel HIV-related diffuse large B-cell lymphoma signature. International Journal of Cancer, 2019, 145(11): 3078-3088.
doi: 10.1002/ijc.32381
pmid: 31044434
|
|
|
| [61] |
Fedoriw Y, Selitsky S, Montgomery N D, et al. Identifying transcriptional profiles and evaluating prognostic biomarkers of HIV-associated diffuse large B-cell lymphoma from Malawi. Modern Pathology, 2020, 33(8): 1482-1491.
doi: 10.1038/s41379-020-0506-3
pmid: 32080349
|
|
|
| [62] |
Aigner P, Just V, Stoiber D. STAT3 isoforms: alternative fates in cancer? Cytokine, 2019, 118: 27-34.
doi: S1043-4666(18)30300-4
pmid: 30031681
|
|
|
| [63] |
闻照凤, 黄绮堂, 胡泉泉, 等. 弥漫大B细胞淋巴瘤中p-STAT3的表达与临床预后及肿瘤相关巨噬细胞的关系. 临床与实验病理学杂志, 2023, 39(2)157-161, 168.
|
|
|
| [63] |
Wen Z F, Huang Q T, Hu Q Q, et al. Clinical prognostic value of p-STAT 3 in diffuse large B-cell lymphoma and its correlation with tumor-associated macrophages. Chinese Journal of Clinical and Experimental Pathology, 2023, 39(2)157-161, 168.
|
|
|
| [64] |
Zou S L, Tong Q Y, Liu B W, et al. Targeting STAT3 in cancer immunotherapy. Molecular Cancer, 2020, 19(1): 145.
doi: 10.1186/s12943-020-01258-7
pmid: 32972405
|
|
|
| [65] |
Tamma R, Ingravallo G, Gaudio F, et al. STAT3, tumor microenvironment, and microvessel density in diffuse large B cell lymphomas. Leukemia & Lymphoma, 2020, 61(3): 567-574.
|
|
|
| [66] |
高波, 孙晶晶, 段月勋, 等. STAT3在艾滋病相关弥漫性大B细胞淋巴瘤中的表达及意义. 临床与病理杂志, 2016, 36(11): 1744-1749.
|
|
|
| [66] |
Gao B, Sun J J, Duan Y X, et al. Expression and significance of STAT 3 in AIDS-related diffuse large B-cell lymphoma. Journal of Clinical and Pathological Research, 2016, 36(11): 1744-1749.
|
|
|
| [67] |
Naor D, Wallach-Dayan S B, Zahalka M A, et al. Involvement of CD44, a molecule with a thousand faces, in cancer dissemination. Seminars in Cancer Biology, 2008, 18(4): 260-267.
doi: 10.1016/j.semcancer.2008.03.015
pmid: 18467123
|
|
|
| [68] |
Drillenburg P, Pals S T. Cell adhesion receptors in lymphoma dissemination. Blood, 2000, 95(6): 1900-1910.
pmid: 10706853
|
|
|
| [69] |
Horst E, Meijer C J, Radaszkiewicz T, et al. Adhesion molecules in the prognosis of diffuse large-cell lymphoma: expression of a lymphocyte homing receptor (CD44), LFA-1 (CD11a/18), and ICAM-1 (CD54). Leukemia, 1990, 4(8): 595-599.
pmid: 1974938
|
|
|
| [70] |
Chao C, Silverberg M J, Chen L H, et al. Novel tumor markers provide improved prediction of survival after diagnosis of human immunodeficiency virus (HIV)-related diffuse large B-cell lymphoma. Leukemia & Lymphoma, 2018, 59(2): 321-329.
|
|
|
| [71] |
Kanapathipillai M. Treating p53 mutant aggregation-associated cancer. Cancers, 2018, 10(6): 154.
doi: 10.3390/cancers10060154
|
|
|
| [72] |
Qin Y, Jiang S Y, Liu P, et al. Characteristics and management of TP53-mutated diffuse large B-cell lymphoma patients. Cancer Management and Research, 2020, 12: 11515-11522.
doi: 10.2147/CMAR.S269624
|
|
|
| [73] |
Scherer F, Kurtz D M, Newman A M, et al. Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA. Science Translational Medicine, 2016, 8(364): 364ra155.
|
|
|
| [74] |
Roschewski M, Dunleavy K, Pittaluga S, et al. Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study. The Lancet Oncology, 2015, 16(5): 541-549.
doi: 10.1016/S1470-2045(15)70106-3
|
|
|
| [75] |
Sidaway P. ctDNA predicts outcomes in DLBCL. Nature Reviews Clinical Oncology, 2018, 15(11): 655.
doi: 10.1038/s41571-018-0092-1
pmid: 30177683
|
|
|
| [76] |
Yao L Y, Xu H, Wo J S, et al. Prognostic value of circulating tumor DNA in lymphoma: a meta-analysis. Clinical and Experimental Medicine, 2022, 22(1): 1-7.
doi: 10.1007/s10238-021-00718-8
|
|
|
| [77] |
Kurtz D M, Scherer F, Jin M C, et al. Circulating tumor DNA measurements As early outcome predictors in diffuse large B-cell lymphoma. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 2018, 36(28): 2845-2853.
doi: 10.1200/JCO.2018.78.5246
|
|
|
| [78] |
Wislez M, Domblides C, Greillier L, et al. Circulating tumor DNA in advanced non-small-cell lung cancer patients with HIV is associated with shorter overall survival: results from a Phase II trial (IFCT-1001 CHIVA). Lung Cancer, 2021, 157: 124-130.
doi: 10.1016/j.lungcan.2021.05.013
pmid: 34016488
|
|
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
| |
Shared |
|
|
|
|
| |
Discussed |
|
|
|
|
